Antiplatelet thromboprophylaxis of arterial vascular diseases and organovascular ischemic diseases
Authors:
Peter Gavorník 1; Andrej Dukát 1,2; Ľudovít Gašpar 1,3; Eva Gavorníková 1,4; Naďa Hučková 1,5; Anna Petrášová 6; Gabriela Gubo 1; Iveta Gašparová 1,7; Lujza Sabolová 8
Authors place of work:
Angiologická sekcia Slovenskej lekárskej komory, Bratislava, Slovenská republika
1; V. interná klinika LF UK a UNB, Bratislava, Slovenská republika
2; I. interná klinika LF UK a UNB, Bratislava, Slovenská republika
3; Ambulancia všeobecného lekárstva pre dospelých, Poliklinika Ružinov, Bratislava, Slovenská republika
4; III. interná klinika LFUK a UNB, Bratislava, Slovenská republika
5; Lekáreň Salvator, Prosalute, Modra, Slovenská republika
6; Ústav lekárskej biológie, genetiky a klinickej genetiky LF UK, Bratislava, Slovenská republika
7; Onkologický ústav svätej Alžbety, Bratislava, Slovenská republika
8
Published in the journal:
Vnitř Lék 2017; 63(2): 124-132
Category:
Guidelines
Summary
Antiplatelet therapy by acetylsalicylic acid (ASA, aspirin) provided pivotal advances in the prevention and treatment of organovascular (angiovascular, cardiovascular, cerebrovascular, extremitovascular, renovascular, genitovascular, mesenteriointestinokolonovascular, bronchopulmovascular, oculovascular, otovascular and other) arterial ischemic diseases. Currently available antiplatelet drugs have some limitations which might be overcomed by improved dosing regimens, use of combination of agents affecting different platelet functions and, in particular, by the new antiplatelet drugs (new arterial antithrombotics) with distinct pharmacodynamic properties offering new advantages, including faster onset of action, greater potency, and reversibility of effects.
Key words:
arteriothromboprophylaxis – arterial thrombosis – classic antiplatelet drugs – new antiplatelet agents – organovascular arterial diseases
Zdroje
1. Gavorník P. Angiológia pre všeobecných praktických lekárov. 2. Arteriológia. Dr. Josef Raabe: Bratislava 2014. ISBN 978–80–8140–168–8.
2. Gavorník P, Dukát A, Gašpar Ľ. Súčasnosť a budúcnosť farmako-artériotromboprofylaxie v klinickej praxi. Odporúčania Angiologickej sekcie Slovenskej lekárskej komory. Vnitř Lék 2013; 59(12): 1081–1087.
3. Poredoš P, Jezovnik MK, Kalodiki E et al. Medical management of patients with peripheral arterial disease. Int Angiol 2015; 34(1): 75–93.
4. Guyatt GH, Norris SL, Schulman S et al. [American College of Chest Physicians]. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): 53S-70S.
5. Eikelboom JW, Hirsh J, Spencer FA et al. Antiplatelet drugs. In: Antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians (ACCP) evidence-based clinical practice guidelines. Chest 2012; 141(2 Suppl): e89S-e119S. Dostupné z DOI: <http://dx.doi.org/10.1378/chest.11–2293>.
6. Tanriover MD, Rigby S, van Hulstejin LH et al. [Working Group on Professional Issues, European Federation of Internal Medicine (EFIM)]. What is the role of general internists in the tertiary or academic setting? Eur J Int Med 2015; 26(1): 9–11. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ejim.2014.11.004>.
7. Sorita A, Ahmed A, Starr SR et al. Off-hour presentation and outcomes in patients with acute ischemic stroke: A systematic review and meta-analysis. Eur J Int Med 2014; 25(4): 394–400. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ejim.2014.03.012>.
8. Kriška M, Gajdošík J, Dukát A et al (eds). Zlyhanie farmakoterapie. Možnosti prevencie. Slovak Academic Press: Bratislava 2015. ISBN 978–80–8960733–4.
9. Birns J, Qureshi S, CHen R et al. Endovascular stroke therapy. Eur J Int Med 2014; 25(7): 584–591. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ejim.2014.06.025>.
10. Gavorník P, Dukát A, Gašpar Ľ et al. Cerebrovaskulárna aterosklerotická choroba ako jedna z mnohých orgánovaskulárnych chorôb systémovej aterosklerózy. Ateroskleróza 2015; 19(1–2): 700–709.
11. Gašpar Ľ, Gašparová I. Význam ambulantného monitorovania krvného tlaku a ambulantného monitorovania EKG u pacientov s koronárnou chorobou srdca. Forum Diab 2015; 4(1): 45–49.
12. Jauch EC, Saver JL, Adams HP et al. [American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Peripheral Vascular Disease, and Council on Clinical Cardiology]. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2013; 44(3): 870–947. Dostupné z DOI: <http://dx.doi.org/10.1161/STR.0b013e318284056a>.
13. Roffi M, Patrono C, Collet JP et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37(3): 267–315. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehv320>.
14. Steg G, James SK, Atar D et al. [Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)]. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33(20): 2569–2619. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehs215>.
15. Parekh PJ, Oldfield EC, Johnson DH. Current Strategies to Reduce Gastrointestinal Bleeding Risk Associated with Antiplatelet Agents. Drugs 2015; 75(14): 1613–1625. Dostupné z DOI: <http://dx.doi.org/10.1007/s40265–015–0455–1>.
16. Rogers KC, Oliphant CS, Finks SW. Clinical Efficacy and Safety of Cilostazol: Critical Revue of the Literature. Drugs 2015; 75(4): 377–395. Dostupné z DOI: <http://dx.doi.org/10.1007/s40265–015–0364–3>.
17. Gavorník P, Dukát A, Gašpar Ľ et al. Choroby aorty – diagnostika, klasifikácia a princípy manažmentu. Kardiol Rev Int Med 2014; 16(6): 493–500.
18. Remková A, Remko M. Antitrombotiká v klinickej praxi. Samedi: Bratislava 2014. ISBN 978–80–970825–8-1.
19. Ntalas IV, Milionis HJ, Kei AA et al. Antiplatelet Treatment in the Secondary Prevention of Coronary and Cerebrovascular Disease. Is There any Place for Novel Agents? Angiology 2014; 65(6): 473–490. Dostupné z DOI: <http://dx.doi.org/10.1177/0003319713499609>.
20. Raparelli V, Proietti M, Napoleone L et al. Asymptomatic peripheral artery disease and antiplatelet management. VASA 2014; 43(5): 309–325. Dostupné z DOI: <http://dx.doi.org/10.1024/0301–1526/a000369>.
21. Andreotti F, Rocca B, Husted S et al. [ESC Thrombosis Working Group]. Antithrombotic therapy in the elderly: expert position paper of the European Society of CardiologyWorking Group on Thrombosis. Eur Heart J 2015; 36(46): 3238–3249. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehv304>.
22. Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014. Eur Heart J 2015; 36(47): 3320–3331. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehv511>.
23. Camici GG, Savarese G, Akhmedov A et al. Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease. Eur Heart J 2015; 36(48): 3392–3403. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehv587>.
24. Diener HC, Cunha L, Forbes C et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143(1–2): 1–13.
25. Dawson DL, Cutler BS, Hiatt WR et al. A comparison of cilostazol and pentoxyfylline for treating intermittent claudication. Am J Med 2000; 109(7): 523–530.
26. Gavorník P. Ateroskleróza a iné choroby tepien. Univerzita Komenského Bratislava: 1999. ISBN 80–223–1422–6.
27. Gavorník P. Angiológia 1 pre všeobecných praktických lekárov. Flebológia. Dr. Josef Raabe: Bratislava 2013. ISBN 978–80–8140–083–4.
28. Fortuna LA, Pawlovski PA, Parker ED et al. Proton pump inhibitor use by aspirin-treated coronary artery disease patients is not associated with increased risk of cardiovascular events. Eur Heart J Cardiovasc Pharmacother 2016; 2(1): 13–19. Dostupné z DOI: <http://dx.doi.org/10.1093/ehjcvp/pvv036>.
29. Myles PS, Smith JA, Forbes A et al. [ATACAS Investigators of the ANZCA Clinical Trials Network]. Stopping vs. Continuing Aspirin before Coronary Artery Surgery. N Engl J Med 2016; 374(8): 728–737. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1507688>.
30. Lüscher TF. Coronary and peripheral interventions: an update. Eur Heart J 2016; 37(14): 1085–1087. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw107>.
31. Cortese B, Granada JF, Scheller B et al. Drug-coated balloon treatment for lower extremity vascular disease intervention: an international positioning document. Eur Heart J 2016; 37(14): 1096–1103. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehv204>.
32. Jolly SS, Natarajan MK. Vascular access and antiplatelet therapies: does one influence the other? Eur Heart J 2016; 37(14): 1131–1132. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehv570>.
33. Riegger J, Byrne RA, Joner M et al. [Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort (PRESTIGE) Investigators]. Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium. Eur Heart J 2016; 37(19): 1538–1549. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehv419>.
34. Hricák V. Akútne koronárne syndrómy. Treba zmeniť klasickú protidoštičkovú liečbu na novú? Benefit, riziko a ako? Cardiology Lett 2016; 25(5): 389–391.
35. Gavorník P, Fialová V. Antitrombocytová antitrombotická prevencia a liečba vaskulárnych a orgánovovaskulárnych artériových chorôb. Interná Med 2016; 16(1): 27–31.
36. Levine GN, Bates ER, Bittl JA et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation 2016; 134: e123-e155. Dostupné z DOI: <http://dx.doi.org/10.1161/CIR.0000000000000404>.
37. Foley TR, Waldo SW, Armstrong EJ. Antithrombotic therapy in peripheral artery disease. Vasc Med 2016; 21(2): 156–169. Dostupné z DOI: <http://dx.doi.org/10.1177/1358863X15622987>.
38. Xhelili E, Eichelberger B, Kopp CW et al. The Antiplatelet Effect of Clopidogrel Decreases With Patient Age. Angiology 2016; 67(10): 902–908.Dostupné z DOI: <http://dx.doi.org/10.1177/0003319716631249>.
39. Beavers CJ, Carris NW, Ruf KM. Management Strategies for Clopidogrel Hypersensitivity. Drugs 2015; 75(9): 999–1007. Dostupné z DOI: <http://dx.doi.org/10.1007/s40265–015–0414-x>.
40. Rollini F, Franchi F, Angiolillo DJ. Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol 2016; 13(1): 11–27. Dostupné z DOI: <http://dx.doi.org/10.1038/nrcardio.2015.113>.
41. Gavorník P, Dukát A, Gašpar Ľ et al. Erektilná dysfunkcia ako prvý znak systémových cievnych chorôb a orgánovaskulárnych artériových ischemických chorôb. Odporúčania a výzva Angiologickej sekcie Slovenskej lekárskej komory (2015). Vnitř Lék 2015; 61(7–8): 660–669.
42. Germain DP, Hughes DA, Nicholls K et al. Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat. N Engl J Med 2016; 375(6): 545–555. Dostupné z DOI:<http://dx.doi.org/10.1056/NEJMoa1510198>.
43. Hollak CEM, Biegstraaten M, Levi M et al. Post-authorisation assessment of orphan drugs. Lancet 2015; 386(10007): 1940–1941. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(15)00827–2>.
44. Palmerini T, Benedetto U, Bacchi-Reggiani L et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet 2015; 385(9985): 2371–2382. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(15)60263-X>.
45. Tendera M, Aboyans V, Bartelink ML et al. [European Stroke Organisation]. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011; 32(22): 2851–2906. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehr211>.
46. Halvorsen S, Storey RF, Rocca B et al on behalf of the ESC Working Group on Thrombosis. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: Expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J 2016; 0: 1 – 11. doi:10.1093/eurheartj/ehw454. First published online: October 27, 2016.
47. Hiatt WR, Fowkes FGR, Heizer G et al. for the EUCLID Trial Steering Committee and Investigators. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med 2017; 376 (1): 32 – 40.
Štítky
Diabetology Endocrinology Internal medicineČlánok vyšiel v časopise
Internal Medicine
2017 Číslo 2
Najčítanejšie v tomto čísle
- Autoantibodies in systemic connective tissue disease and ANCA-associated vasculitis, their relationship to interstitial lung diseases and prognosis
- Parathyroid cancer
- Long-acting insulins in the treatment of type 2 diabetes and their position in the current treatment algorithm
- Acute kidney injury: a current comprehensive overview